Centum Electronics Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/3p3jmsodxxfomkei2y5h26x1.pdf

Key Takeaways


Standalone vs Subsidiary: A Tale of Two Businesses

Nikhil Mallavarapu: "So, at the subsidiary level, we expect it to be profitable in the next two quarters itself."

Margin Walk & Targets

K. S. Desikan: "But as we have been saying, you know, with the current profile and the order book and what we have done in 6 months, we should be able to get a 10% for the company."

Demand Drivers: Structural, Not Cyclical

Nikhil Mallavarapu: "They are not shifting all their manufacturing, first of all. So, they are derisking the supply chain, which means that they will continue to source from China, but they want to have a second source or destination to source from."

Order Book & Pipeline Visibility

Nikhil Mallavarapu: "Yes, we are fairly confident. I mean, we can never be sure until it gets there, but we are fairly confident."

Segment & Geographic Updates

Segment / GeographyTrendCommentary
Standalone BTS▲ StrongRevenue up 53% YoY; new customer ramp-ups in industrial, e-mobility and defense exports; big orders closed, more expected in H2.
EMS▲ StrongPrimary driver of 23% consolidated revenue growth; EV, cleantech and defense export demand all contributing.
Subsidiary (Europe)▼ WeakRevenue down 14% QoQ; seasonally slow summer plus legacy fixed-price overruns; EBITDA break-even.
Canada▼ Negative marginSteadily improving but still negative; no specific break-even timeline given.
Domestic Defense & Space▲ Expected H2 driverPositioned as a major contributor in H2; Atma Nirbhar policy pushing indigenous sourcing.
Healthcare▬ Engineering phaseNew opportunities in France for point-of-care telemedicine devices; production expected next year.

Strategic Positioning & Capex

Nikhil Mallavarapu: "About 75% of our business is coming from overseas. So, you know, some of the growth drivers that we are seeing are a result of, there is a China plus one strategy where customers are looking to derisk their supply chain and bring business to India or other policy initiatives by the government itself to drive Make in India kind of opportunities, and these are sort of structural, microeconomic shifts that are happening."

Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated operating marginAchieve 10% for full yearFY24
Subsidiary profitabilityProfitable at subsidiary level (including French business)Next two quarters (Q3/Q4 FY24)
Engineering services marginFirst step to 9%-10%, then to 14%-15%2-3 year horizon
Consolidated EBITDA marginMid-teens on a consolidated basis3-5 year horizon
Revenue growth20% growth with margin improvementsNext 2-3 years
Debt reductionSignificantly down from current levelsBy FY24 year-end
New EMS customer scaleAt least \$10 mn annualized per new customerNot far from target in coming quarter
Big-ticket BTS ordersOrders that slipped from Q2 to closeQ3 or at worst Q4 FY24
Healthcare point-of-care devicesMove from engineering phase to productionNext year
CapexMaintenance capex of ₹10-15 cr per annum; no step-up unless Indra/Rafael opportunities materializeOngoing

Key Metrics

MetricQ2 FY24
Consolidated revenue₹248 cr, +23% YoY, flat QoQ
Standalone revenue₹160 cr, +53% YoY and +25% QoQ
Subsidiary (Centum T&S) revenue₹98 cr, -14% QoQ, almost flat YoY
Consolidated EBITDA₹17 cr, 6.9% margin vs 8.5% QoQ and 4.1% YoY
Standalone EBITDA₹21 cr, 13.2% margin vs 3.2% YoY
Standalone EBT₹13 cr, significantly higher QoQ and YoY
Consolidated H1 FY24 EBITDA margin7.8%, vs 4.8% in H1 FY23
Full-year consolidated EBITDA margin guidance~10%
Order book₹1,548 cr, flat over last couple of quarters
H1 FY24 revenue growth21% YoY, ₹496 cr vs ₹410 cr in H1 FY23
Consolidated working capital79–80 days, flat QoQ
Standalone working capital135 days, improved from 140 days in Q4 FY23
Consolidated debt₹298 cr, increased from ₹263 cr in March
Standalone debt₹143 cr, increased from ₹106 cr in March, including ₹15 cr term loan for capex
Subsidiary debt₹155 cr, marginally reduced from ₹157 cr QoQ, down ~€1 mn from March
Healthcare segment revenue share~9% of total revenue
Overseas business share~75% of total business
Stake in subsidiary90.1%, all put option obligations completed
FY24 planned capex~₹30 cr, ₹20 cr already spent; maintenance capex ~₹10–15 cr per annum thereafter